NCT07049783 Examining the Circadian Timing Effects of the Hypotensive Response to Exercise
| NCT ID | NCT07049783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Freda Patterson |
| Condition | Young Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-22 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-07-22 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn how exercise timing affects blood pressure in adults with elevated or high blood pressure. Exercise can influence the body's natural 24-hour rhythms, including blood pressure patterns. A single exercise session can lower blood pressure for up to 24 hours, but it is not fully understood how the time-of-day for exercise affects this response. The main question this study aims to answer is: • When the same participant exercises at different times of day (morning, afternoon, or evening), how does this affect the participant's blood pressure over the next 24 hours? Participants will: * Undergo an in-lab assessment of individual biological rhythm that will indicate the clock-time for an individual's biological night * Complete 3 supervised treadmill exercise sessions * 1 in the biological morning (biological night + 10 hours) * 1 in the biological afternoon (biological night + 15 hours) * 1 in the biological evening (biological night + 20 hours) * Complete a 24-hour blood pressure assessment before and after each exercise session
Eligibility Criteria
Inclusion Criteria: * 18-39 Years old * Resting blood pressure greater than or equal to 120/80 mmHg or less than 140/90 mmHg Exclusion Criteria: * Diagnosis or history of chronic or autoimmune disease (i.e., cardiovascular, metabolic, renal, endocrine, cancer) * Diagnosis or history of sleep disorder (i.e., obstructive sleep apnea, insomnia, restless leg syndrome) * Alcohol or drug dependence * Elevated risk for sleep disorders * Elevated risk for clinical depression * Normotensive (blood pressure less than 120/80 mmHg) or stage 2+ hypertension (blood pressure greater than or equal to 140/90 mmHg) * Body mass index less than 18.5 or greater than 35 kg/m2 * Self-reported use of sleep medications/supplements (e.g., melatonin) * Self-reported use of medications influencing vascular physiology (e.g., antihypertensive medications, weight loss medications) * Highly physically active (greater than or equal to 300 minutes moderate-to-vigorous physical activity per week) * Currently pregnant or breastfeeding * Current tobacco use (greater than or equal to 1 cigarette in the past month) * Nighttime or rotating shift work within the last 3 months * Contraindications to aerobic exercise
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07049783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Young Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07049783 currently recruiting?
Yes, NCT07049783 is actively recruiting participants. Contact the research team at fredap@udel.edu for enrollment information.
Where is the NCT07049783 trial being conducted?
This trial is being conducted at Newark, United States.
Who is sponsoring the NCT07049783 clinical trial?
NCT07049783 is sponsored by Freda Patterson. The trial plans to enroll 30 participants.